Skip to main content
Delfa

← All trials/NCT07012642

RecruitingPhase EARLY_1

Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

Asset

GLP-1 / incretin class catch-all

Listed sites

2

Recruiting sites

2

Estimated enrollment

110

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥23

Primary endpoint

•Patient reported quality of life outcome

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07012642
Org study IDGLP-1 in Lymphedema

Timeline

Milestones

Study start2025-04-09actual
Study first posted2025-06-10actual
Last update posted2025-06-10actual
Primary completion2027-04-09estimated
Study completion2027-04-09estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

Adults 18 years or older with unilateral upper or lower extremity lymphedema Limb volume > 5% BMI => 23 Oncology clearance if there is a cancer history

Exclusion criteria

Moderate to severe venous insufficiency Actively using GLP-1 RAs Known intolerance or adverse effect to GLP-1 RAs Medical history or morbidity where GLP-1 RAs are contraindicated as per patient's primary care provider such as MEN syndrome or history of thyroid cancer.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL
1
Other (unclassified)
1

Patient-reported / QoL

1 endpoint
Primary/protocol endpoint

Patient reported quality of life outcome using LLIS

Time frame:6 months

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Physiological improvement

Time frame:6 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.